Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) shot up 6% during trading on Wednesday . The stock traded as high as $7.47 and last traded at $7.39. 21,203 shares changed hands during mid-day trading, a decline of 52% from the average session volume of 44,337 shares. The stock had previously closed at $6.97.
Analyst Upgrades and Downgrades
Separately, HC Wainwright began coverage on shares of Actuate Therapeutics in a research note on Monday, March 17th. They issued a "buy" rating and a $20.00 price objective on the stock.
Read Our Latest Analysis on ACTU
Actuate Therapeutics Price Performance
The stock's 50-day moving average is $7.41 and its 200 day moving average is $8.01.
Hedge Funds Weigh In On Actuate Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the business. Freestone Capital Holdings LLC acquired a new stake in shares of Actuate Therapeutics in the fourth quarter valued at about $80,000. Envestnet Asset Management Inc. acquired a new position in Actuate Therapeutics during the fourth quarter worth $83,000. OMERS ADMINISTRATION Corp bought a new stake in Actuate Therapeutics during the fourth quarter worth $84,000. Sigma Planning Corp acquired a new stake in Actuate Therapeutics in the fourth quarter valued at $128,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in shares of Actuate Therapeutics in the 4th quarter valued at about $130,000.
Actuate Therapeutics Company Profile
(
Get Free Report)
Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.
See Also
Before you consider Actuate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Actuate Therapeutics wasn't on the list.
While Actuate Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
